> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel Backs Galleri Cancer Test After Split Vote
- URL: https://www.theamericanquorum.com/fda-panel-backs-galleri-cancer-test-split-vote/
- Published: 2026-09-24T04:51:43.000Z
- Updated: 2026-09-24T04:51:43.000Z
- Description: FDA advisers backed Grail’s Galleri blood test for adults 50 and older, despite a narrow effectiveness vote. The decision now turns on how regulators weigh broad detection potential against uncertain population-level benefit.
- Author: News Desk
- Tags: Policy

Federal advisers backed Grail’s Galleri blood test Wednesday after voting 10-0 that it is safe, 6-4 that it is effective and 7-2, with one abstention, that its benefits outweigh its risks. The split recommendation moves the United States closer to its first Food and Drug Administration-approved blood test designed to screen broadly for multiple cancers, while leaving the agency to decide how much uncertainty is acceptable for a test intended for millions of people without symptoms.

The votes are advisory, not an approval. The [FDA](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting?ref=theamericanquorum.com) says its expert committees provide nonbinding recommendations, and the agency will make the final decision on Grail’s premarket approval application. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/fda-advisers-back-safety-grails-cancer-test-narrowly-endorses-efficacy-2026-09-23/?ref=theamericanquorum.com) reported that a decision is expected in the coming months.

## What Galleri is designed to do

Galleri is a prescription-only laboratory test proposed for adults 50 and older. It uses next-generation sequencing to look for cancer-associated methylation patterns in cell-free DNA circulating in blood. A positive result includes a prediction of where the signal may have originated, but it does not diagnose cancer; it directs a patient and clinician toward imaging, biopsy or another diagnostic workup.

The distinction matters. The proposed label says a negative result does not rule out cancer and that Galleri is not a substitute for established breast, cervical, colorectal, lung or prostate screening. The FDA’s [review](https://www.fda.gov/media/194909/download?ref=theamericanquorum.com) warns that a false positive can expose a healthy person to invasive procedures, anxiety and cost, while a false negative can create reassurance that delays diagnosis or discourages proven screening.

The potential public-health gain is also substantial. FDA reviewers estimate that the United States will record more than 2.1 million new cancer cases and nearly 630,000 cancer deaths in 2026\. About 58% of those deaths are expected to involve cancers for which the U.S. Preventive Services Task Force has no grade A, B or C screening recommendation. A single blood draw that reliably finds some of those cancers could fill a large gap, particularly if patients continue existing screening.

## Strong specificity, limited sensitivity

The central U.S. evidence came from PATHFINDER 2, a prospective study of adults eligible for screening. In the FDA’s analysis, the test’s 12-month sensitivity was 35.0%, meaning it detected roughly one in three cancers diagnosed during the follow-up period. Specificity was 99.85%, and 77.0% of positive results were followed by a cancer diagnosis within 12 months. Grail’s [submission](https://www.fda.gov/media/194910/download?ref=theamericanquorum.com) also reported 94.3% accuracy in predicting the cancer signal’s origin among detected cases.

Those measures answer different questions. High specificity limits false alarms across a large screened population, but 35% sensitivity means most cancers diagnosed during the study period did not produce a positive Galleri result. Performance also varied by cancer type and stage. The panel therefore had to judge a test that may identify otherwise unscreened cancers without evidence that a negative result can safely change any patient’s care.

The evidence was further complicated by the randomized NHS-Galleri trial in Britain. The 142,000-participant study did not meet its primary endpoint of significantly reducing combined stage III and IV diagnoses among 12 prespecified cancers after three annual screening rounds. The published [results](https://ascopubs.org/doi/10.1200/JCO.2026.44.17%5Fsuppl.LBA100?ref=theamericanquorum.com) recorded 706 late-stage cancers in the intervention group and 688 in the control group. An [ASCO](https://www.asco.org/about-asco/press-center/galleri-early-detection-shift-timing-cancer-detection?ref=theamericanquorum.com) summary noted a reduction in stage IV diagnoses, a secondary finding, but that does not erase the missed primary endpoint or establish a mortality benefit.

## The policy question extends beyond accuracy

For regulators, the issue is not simply whether the assay can find cancer-associated DNA. A population screening program must produce enough earlier, actionable diagnoses to outweigh downstream testing, overdiagnosis and false reassurance. That balance depends on how physicians explain results, which diagnostic pathways follow a positive test and whether patients continue recommended screening.

The panel’s narrow effectiveness vote reflected that gap between test performance and proven health outcome. [STAT](https://www.statnews.com/2026/09/23/fda-advisory-panel-recommends-approval-grail-galleri-multi-cancer-blood-test/?ref=theamericanquorum.com) reported that several advisers saw meaningful promise while emphasizing the need for clear labeling and continued evidence collection. FDA reviewers likewise asked how benefits, risks and limitations should be communicated to support shared decisions.

Approval would also influence clinical guidelines, employer benefits and insurer decisions, although it would not automatically produce broad coverage. Galleri is already sold as a laboratory-developed test under federal laboratory rules, but it is not FDA-approved. Premarket approval would give the agency authority over the specific indication and labeling while supplying a regulatory precedent for other multi-cancer detection tests.

## What FDA must decide

The agency can approve the application, reject it or seek additional information. If it approves Galleri, the most consequential details may be the final label and any postmarket requirements: how often adults should be screened, how clinicians should respond to a positive result, what patients must be told about missed cancers, and what long-term outcomes Grail must continue measuring.

Wednesday’s recommendation is therefore a milestone, not a resolution. The panel concluded that Galleri’s promise exceeds its risks by a narrow margin. FDA must now determine whether the evidence is strong enough for national clinical use—and how to prevent a new screening tool from being mistaken for a diagnosis or a replacement for the screening methods already known to save lives.